keyword
MENU ▼
Read by QxMD icon Read
search

Breast chemotherapy adjuvant and primary

keyword
https://www.readbyqxmd.com/read/28803675/the-yale-fitness-intervention-trial-in-female-cancer-survivors-cardiovascular-and-physiological-outcomes
#1
M Tish Knobf, Sangchoon Jeon, Barbara Smith, Lyndsay Harris, Siobhan Thompson, Mitchel R Stacy, Karl Insogna, Albert J Sinusas
BACKGROUND: Induced premature menopause and cardio-toxic therapy increase cardiovascular disease risk in female cancer survivors. OBJECTIVE: To compare the effects of a 12 month aerobic-resistance fitness center intervention to home based physical activity on cardiovascular function and metabolic risk factors. METHODS: Subjects (N = 154) who had completed primary and/or adjuvant chemotherapy (past 3 years) were randomized to a fitness center intervention or a home based group...
August 10, 2017: Heart & Lung: the Journal of Critical Care
https://www.readbyqxmd.com/read/28800861/ipatasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line-therapy-for-metastatic-triple-negative-breast-cancer-lotus-a-multicentre-randomised-double-blind-placebo-controlled-phase-2-trial
#2
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga
BACKGROUND: The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer. METHODS: In this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium...
August 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28798006/breast-adenoid-cystic-carcinoma-a-rare-case-report-and-review-of-the-literature
#3
Lamiae El Amarti, Hanan Raiss, Mohamed Layachi, Salif Baldé, Hamza Ettahri, Ibrahim Elghissassi, Hind Mrabti, Hassan Errihani
BACKGROUND: Primary adenoid cystic carcinoma (ACC) of the breast is a rare subtype of invasive breast cancer. It has a particular interest because of its excellent prognosis conversely to other triple-negative breast cancers that are associated with poor prognosis. The place of chemotherapy and radiotherapy remains controversial and there is no consensus on optimal management of the ACC of the breast. CASE REPORT: A 50-year-old woman, presented with a palpable right breast lump...
May 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28797032/comprehensive-geriatric-assessment-in-326-older-women-with-early-breast-cancer
#4
D O Okonji, R Sinha, I Phillips, D Fatz, A Ring
BACKGROUND: One-third of new early breast cancer diagnoses occur in women over 70 years old. However, older women are less likely to receive radical curative treatments. This study prospectively evaluated a cohort of older women using a Comprehensive Geriatric Assessment (CGA) to determine whether fitness explained the apparent under-treatment in this patient group. METHODS: In this multi-centre prospective study, patients aged ⩾70 years with Stages I-III breast cancer underwent a pretreatment baseline CGA consisting of eight assessment tools...
August 10, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28780480/adjuvant-chemotherapy-in-pt1ab-node-negative-triple-negative-breast-carcinomas-results-of-a-national%C3%A2-multi-institutional-retrospective-study
#5
A de Nonneville, A Gonçalves, C Zemmour, M Cohen, J M Classe, F Reyal, P E Colombo, E Jouve, S Giard, E Barranger, R Sabatier, F Bertucci, J M Boher, G Houvenaeghel
BACKGROUND: Triple-negative breast cancers (TNBCs) are considered as associated with poor outcome, but prognosis of subcentimetric, node-negative disease remains controversial and evidence that adjuvant chemotherapy (CT) is effective in these small tumours remains limited. PATIENTS AND METHODS: Our objective was to investigate the impact of CT on survival in pT1abN0M0 TNBC. Patients were retrospectively identified from a cohort of 22,475 patients who underwent primary surgery in 15 French centres between 1987 and 2013...
August 3, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28779904/ixabepilone-and-carboplatin-for-hormone-receptor-positive-her2-neu-negative-and-triple-negative-metastatic-breast-cancer
#6
Cynthia Osborne, Jagathi D Challagalla, Charles F Eisenbeis, Frankie Ann Holmes, Marcus A Neubauer, Nicholas W Koutrelakos, Carlos A Taboada, Sasha J Vukelja, Sharon T Wilks, Mary Ann Allison, Praveen Reddy, Scot Sedlacek, Yunfei Wang, Lina Asmar, Joyce O'Shaughnessy
BACKGROUND: Hormonal therapies and single-agent sequential chemotherapeutic regimens are the standards of care for HER2(-) metastatic breast cancer (MBC). However, treating patients with hormone-refractory and triple negative (TN) MBC remains challenging. We report the results of combined ixabepilone and carboplatin in a single-arm phase II trial. PATIENTS AND METHODS: In the present prospective analysis of hormone receptor-positive (HR(+))/HER2(-) and TN MBC cohorts, patients could have received 0 to 2 chemotherapy regimens for MBC before enrollment...
July 10, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28764688/developing-a-patient-decision-aid-for-the-treatment-of-women-with-early-stage-breast-cancer-the-struggle-between-simplicity-and-complexity
#7
W Savelberg, T van der Weijden, L Boersma, M Smidt, C Willekens, A Moser
BACKGROUND: A patient decision aid (PtDA) can support shared decision making (SDM) in preference-sensitive care, with more than one clinically applicable treatment option. The development of a PtDA is a complex process, involving several steps, such as designing, developing and testing the draft with all the stakeholders, known as alpha testing. This is followed by testing in 'real life' situations, known as beta testing, and then finalising the definite version. Our aim was developing and alpha testing a PtDA for primary treatment of early stage breast cancer, ensuring that the tool is considered relevant, valid and feasible by patients and professionals...
August 1, 2017: BMC Medical Informatics and Decision Making
https://www.readbyqxmd.com/read/28758147/create-x-a-role-for-capecitabine-in-early-stage-breast-cancer-an-analysis-of-available-data
#8
REVIEW
Jo Anne Zujewski, Lawrence Rubinstein
Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast cancer. One randomized clinical trial (CREATE-X) of capecitabine versus no additional therapy has been conducted in women with early stage breast cancer who received standard chemotherapy pre-operative therapy and had residual invasive breast cancer at the time of surgery...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/28734185/primary-small-cell-neuroendocrine-carcinoma-of-the-breast-a-case-report-and-review-of-the-literature
#9
Abigail Tremelling, Selyne Samuel, Mary Murray
INTRODUCTION: Primary small cell neuroendocrine carcinoma of the breast (SCNCB) is a very uncommon type of breast cancer. Histology and morphology are virtually indistinguishable from small cell neuroendocrine carcinomas of the lung (SCNCL), mandating a search for a primary site elsewhere in the body. There is no standard approach to treatment as there are only a limited number of cases reported in the literature. This report summarizes a case of primary SCNCB and presents a review of the literature...
July 8, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28730323/the-pathogenesis-diagnosis-and-management-of-metastatic-tumors-to-the-ovary-a-comprehensive-review
#10
REVIEW
Ondřej Kubeček, Jan Laco, Jiří Špaček, Jiří Petera, Jindřich Kopecký, Alena Kubečková, Stanislav Filip
Secondary tumors of the ovary account for 10-25% of all ovarian malignancies. The most common tumors that give rise to ovarian metastases include breast, colorectal, endometrial, stomach, and appendix cancer. The correct diagnosis of secondary ovarian tumors may be challenging as they are not infrequently misdiagnosed as primary ovarian cancer, particularly in the case of mucinous adenocarcinomas. The distinction from the latter is essential, as it requires different treatment. Immunohistochemistry plays an important role in distinguishing primary ovarian tumors from extra-ovarian metastases and, furthermore, may suggest the primary tumor site...
July 20, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28726159/diagnosis-and-treatment-delays-among-elderly-breast-cancer-patients-with-pre-existing-mental-illness
#11
Kristy Iglay, Melissa L Santorelli, Kim M Hirshfield, Jill M Williams, George G Rhoads, Yong Lin, Kitaw Demissie
PURPOSE: This study aimed to compare diagnosis and treatment delays in elderly breast cancer patients with and without pre-existing mental illness. METHODS: A retrospective cohort study was conducted using the Surveillance, Epidemiology and End Results-Medicare data including 16,636 women 68+ years, who were diagnosed with stage I-IIIa breast cancer in the United States from 2005 to 2007. Mental illness was identified using International Classification of Diseases, Ninth Revision, Clinical Modification codes recorded on inpatient and outpatient claims during the 3 years prior to breast cancer diagnosis...
July 19, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28715540/predictors-of-hand-foot-syndrome-and-pyridoxine-for-prevention-of-capecitabine-induced-hand-foot-syndrome-a-randomized-clinical-trial
#12
Yoon-Sim Yap, Li-Lian Kwok, Nicholas Syn, Wen Yee Chay, John Whay Kuang Chia, Chee Kian Tham, Nan Soon Wong, Soo Kien Lo, Rebecca Alexandra Dent, Sili Tan, Zuan Yu Mok, King Xin Koh, Han Chong Toh, Wen Hsin Koo, Marie Loh, Raymond Chee Hui Ng, Su Pin Choo, Richie Chuan Teck Soong
Importance: Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective: To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive of HFS. Design, Setting, and Participants: This single-center, randomized double-blind, placebo-controlled phase 3 trial conducted at National Cancer Centre Singapore assessed whether oral pyridoxine could prevent the onset of grade 2 or higher HFS in 210 patients scheduled to receive single-agent capecitabine chemotherapy for breast, colorectal, and other cancers...
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28712671/analysis-of-stereotactic-biopsies-performed-on-suspicious-calcifications-identified-within-24-months-after-completion-of-breast-conserving-surgery-and-radiation-therapy-for-early-breast-cancer-can-biopsy-be-obviated
#13
Rosalind P Candelaria, Palita Hansakul, Alastair M Thompson, Huong Le-Petross, Vicente Valero, Roland Bassett, Monica L Huang, Lumarie Santiago, Beatriz E Adrada
BACKGROUND: To determine the cancer yield of stereotactic biopsy of suspicious calcifications identified within 24 months after breast conservation therapy (BCT). METHODS: Retrospective review of stereotactic biopsies performed during 2009-2013 for suspicious calcifications in the ipsilateral breast of patients who completed BCT. RESULTS: 94/2773 (3.4%) had stereotactic biopsies for suspicious calcifications in the ipsilateral breast; 7/94 (7...
July 1, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28711750/web-based-tailored-psycho-education-for-breast-cancer-patients-at-the-onset-of-the-survivorship-phase-a-multicenter-randomized-controlled-trial
#14
Jolien M Admiraal, Annette W G van der Velden, Jenske I Geerling, Johannes G M Burgerhof, Grietje Bouma, Annemiek M E Walenkamp, Elisabeth G E de Vries, Carolien P Schröder, Anna K L Reyners
CONTEXT: Many breast cancer patients have unmet informational and psychosocial needs after treatment completion. A psycho-educational intervention may be well-suited to support these patients. OBJECTIVES: The purpose of this multicenter randomized controlled trial was to examine the effectiveness of a web-based tailored psycho-educational program (ENCOURAGE) for breast cancer patients which aims to empower patients to take control over prevailing problems. METHODS: Female breast cancer patients from two hospitals in the Netherlands who recently completed (neo-)adjuvant chemotherapy were randomly assigned to standard care or 12-week access to the ENCOURAGE program providing fully automated information, problem-solving strategies, resources and services for reported problems...
July 12, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28706892/primary-osteosarcoma-of-the-breast-a-case-report
#15
Chan Seok Yoon, Sung Soo Kang
Primary osteosarcomas of the breast are extremely uncommon. Here we describe a case of a 77-year-old woman who presented with a hard mass on her right breast. Mammography and breast ultrasound demonstrated a round-shaped calcified mass on the right breast but the features were not definitely diagnostic. For diagnostic purposes, an excisional biopsy was performed and the mass proved to be a primary osteosarcoma of the breast by pathologic findings. PET-CT and whole body bone scan showed neither evidence of metastasis nor underlying bone lesions...
July 2017: Annals of Surgical Treatment and Research
https://www.readbyqxmd.com/read/28702147/does-adjuvant-chemotherapy-change-bone-mineral-density-and-related-serum-biomarkers-in-women-with-breast-cancer
#16
Reza Safaei-Nodehi, Javad Esmaili, Ramazanali Sharifian, Shafieh Movaseghi, Sayeh Parkhideh
BACKGROUND: The primary objective of this study was to assess BMD change in Iranian females with breast cancer. METHODS: A sample of 73 female breast cancer patients treated with adjuvant chemotherapy either alone or followed by radiotherapy between March 2013 and February 2016 were considered for this study. Bone mineral density (BMD) change was evaluated by measuring z-score of lumbar spine, femoral neck (right and left side) as well as biochemical measurements...
2017: Caspian Journal of Internal Medicine
https://www.readbyqxmd.com/read/28692525/effect-of-adjuvant-chemotherapy-on-left-ventricular-remodeling-in-women-with-newly-diagnosed-primary-breast-cancer-a-pilot-prospective-longitudinal-cardiac-magnetic-resonance-imaging-study
#17
Erick Avelar, Quynh A Truong, David Inyangetor, Ravi Marfatia, Clifford Yang, Electra Kaloudis, Susan Tannenbaum, Guido Rosito, Sheldon Litwin
PURPOSE: The aim of this study was to assess the left ventricular (LV) remodeling response to chemotherapy in low-cardiac-risk women with newly diagnosed nonmetastatic breast cancer. Cardiotoxic effects of chemotherapy are an increasing concern. To effectively interpret cardiac imaging studies performed for screening purposes in patients undergoing cancer therapy it is necessary to understand the normal changes in structure and function that may occur. METHODS: Twenty women without preexisting cardiovascular disease, of a mean age of 50 years, newly diagnosed with nonmetastatic breast cancer and treated with anthracycline or trastuzumab were prospectively enrolled and evaluated at four time points (at baseline, during chemotherapy, 2 weeks after chemotherapy, and 6 months after chemotherapy) using cardiac magnetic resonance imaging, blood samples, and a clinical questionnaire...
July 7, 2017: Journal of Thoracic Imaging
https://www.readbyqxmd.com/read/28690652/prognostic-impact-of-progesterone-receptor-status-in-chinese-estrogen-receptor-positive-invasive-breast-cancer-patients
#18
Nan Yao, Zhenchuan Song, Xinle Wang, Shan Yang, Heng Song
PURPOSE: Estrogen receptor (ER) and progesterone receptor (PR) have been used as indicators of endocrine system status since the mid-1970s in the clinical management of breast cancer. The predictive role of ER in endocrine therapy is undisputed, but the prognostic value of PR is still debated. The aim of this study was to investigate the clinical characteristics and prognosis of ER positive breast cancer with different PR expression levels. METHODS: A population cohort of 3,030 primary invasive ER positive breast cancer patients from a single cancer center underwent surgery and received adjuvant endocrine therapy from 2004 to 2010...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28685896/comorbidity-dependent-adherence-to-guidelines-and-survival-in-breast-cancer-is-there-a-role-for-guideline-adherence-in-comorbid-breast-cancer-patients-a-retrospective-cohort-study-with-2137-patients
#19
Daniel Wollschläger, Xiaoyu Meng, Achim Wöckel, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner
In the treatment of breast cancer, decisions on adjuvant treatment reflect individual patient characteristics like age and comorbidity. This study assessed the association between adherence to guidelines for adjuvant treatment and survival while taking into account age at diagnosis and comorbidities. We collected the Charlson comorbidity index at baseline for 2179 women treated for primary breast cancer from 1992 to 2008 who participated in a German retrospective multicenter cohort study. We assessed subsequent adjuvant therapy guideline adherence and survival in relation to baseline comorbidities...
July 7, 2017: Breast Journal
https://www.readbyqxmd.com/read/28682681/de-escalation-strategies-in-human-epidermal-growth-factor-receptor-2-her2-positive-early-breast-cancer-bc-final-analysis-of-the-west-german-study-group-adjuvant-dynamic-marker-adjusted-personalized-therapy-trial-optimizing-risk-assessment-and-therapy-response
#20
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Ronald Ernest Kates, Michael Braun, Sherko Küemmel, Claudia Schumacher, Jochem Potenberg, Stefan Kraemer, Anke Kleine-Tebbe, Doris Augustin, Bahriye Aktas, Helmut Forstbauer, Joke Tio, Raquel von Schumann, Cornelia Liedtke, Eva-Maria Grischke, Johannes Schumacher, Rachel Wuerstlein, Hans Heinrich Kreipe, Ulrike Anneliese Nitz
Purpose Human epidermal growth factor receptor 2 (HER2)-positive/hormone receptor (HR)-positive breast cancer is a distinct subgroup associated with lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little is known about the efficacy of the combination of endocrine therapy (ET) with trastuzumab or with the potent antibody-cytotoxic, anti-HER2 compound trastuzumab emtansine (T-DM1) with or without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer) compares pathologic complete response (pCR) rates of T-DM1 versus trastuzumab with ET in early HER2-positive/HR-positive breast cancer...
July 6, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
43929
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"